4.6 Article

Immunologic control of tumors by in vivo Fcγ receptor-targeted antigen loading in conjunction with double-stranded RNA-mediated immune modulation

期刊

JOURNAL OF IMMUNOLOGY
卷 176, 期 3, 页码 1363-1374

出版社

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.176.3.1363

关键词

-

向作者/读者索取更多资源

Despite the expression of non-self or neo-epitopes, many tumors such as lymphoid malignancies or cancers induced by oncogenic viruses are able to gradually overcome the immune defense mechanisms and spread. Using a preclinical model of hematological malignancy, we show that Ig-associated idiotypic determinants are recognized by the immune system in a fashion that results in immune deviation, allowing tumor progression and establishment of metastases. Using gene-targeted mice, we show that anti-idicitypic MHC class I-restricted immunity is promoted by ITAM motif (ITAM(+)) Fc gamma R, but kept in check by ITIM motif (ITIM+) Fc gamma RIIB-mediated mechanisms. In addition to interfering with the functionality of ITIM+ Fc gamma R, effective anti-idiotypic and antitumoral immunity can be achieved by Fc gamma R-targeted delivery of epitope in conjunction with administration of stimulatory motifs such as dsRNA, correcting the ineffective response to idiotypic epitopes. The immune process initiated by Fc gamma R-mediated targeting of epitope together with dsRNA, resulted in control of tumor growth, establishment of immune memory and protection against tumors bearing antigenic variants. In summary, targeted delivery of MHC class I-restricted epitopes via ITAM(+) Fc gamma R, in conjunction with use of TLR-binding immune stimulatory motifs such as dsRNA, overcomes suboptimal responses to idiotypic determinants and may constitute a novel approach for the treatment of a broad range of malignancies. Finally, the results shed light on the mechanisms regulating the idiotypic network and managing the diversity associated with immune receptors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据